Why the study?
Given known differences between real-world and clinical trial populations, the authors sought to characterize demographics, clinical characteristics, and outcomes of real-world HFrEF patients, including those mirroring clinical trial criteria.
Approximately 40% of real-world HFrEF patients meet the enrollment criteria for the GALACTIC-HF trial, but these trial-eligible patients have higher rates of HF hospitalization and different comorbidity profiles compared to the broader HFrEF population.
No takes yet. Share an insight, caveat, or question.
Real-world HFrEF patients have lower HF hospitalization rates than trial-eligible counterparts; leaves open generalizability of GALACTIC-HF results.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: